A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population - Kivitz, Alan J.; Cohen, Stanley; Keystone, Edward; van Vollenhoven, Ronald F.; Haraoui, Boulos; Kaine, Jeffrey; Fan, Haiyun; Connell, Carol A.; Bananis, Eustratios; Takiya, Liza; Fleischmann, Roy (Seminars in arthritis and rheumatism, 2018)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; and ORAL Standard (NCT00853385); Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Combination therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Keywords; Male; Methotrexate - therapeutic use; Middle Aged; Monotherapy; ORAL Scan (NCT00847613); ORAL Solo (NCT00814307); ORAL Start (NCT01039688); ORAL Step (NCT00960440); ORAL Sync (NCT00856544); Piperidines - adverse effects; Piperidines - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Pyrroles - adverse effects; Pyrroles - therapeutic use; Rheumatoid arthritis; Safety; Tofacitinib; Treatment Outcome; Young Adult; ORAL Sync (NCT00856544); Keywords; ORAL Step (NCT00960440); PY; Combination therapy; ORAL Scan (NCT00847613); Pts; MTX; HDL; SD; HZ; DAS28-4(ESR); LDL; MACE; and ORAL Standard (NCT00853385); ULN; Hb; Safety; BID; BMI; CI; DMARD; IR; SIE; RA; ORAL Solo (NCT00814307); ORAL Start (NCT01039688); Tofacitinib; Rheumatoid arthritis; SAE; TNFi; Monotherapy